| Ytd | -34.24% | |
| 1y | -59.11% |
| Open | 3.85 | Prev Close | 3.88 | Low | 3.80 | High | 3.96 | Mkt Cap | 54.87M |
| Vol | 48.13K | Avg Vol | 100.21K | EPS | -3.52 | P/E | N/A | Forward P/E | -1.34 |
| Beta | 0.41 | Short Ratio | 1.90 | Inst. Own | 12.91% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 4.28 | 200-d Avg | 5.36 | 1yr Est | 45.17 |
CLNN News
Clene NASDAQ: CLNN said it plans to submit a new drug application to the U.S. Food and Drug Administ
Clene Inc. (NASDAQ: CLNN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the
SALT LAKE CITY, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that ma
SALT LAKE CITY, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biote
Gainers PDS Biotechnology (NASDAQ:PDSB) shares rose 63.7% to $0.65 during Tuesday's regular ses
Nathaniel Bradley, Co-Founder and CEO of Datavault AI Inc. (NASDAQ:DVLT), presents today, Tuesday, S
Investment led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington
Investment led by Clene's Chairman of the Board of Directors, alongside founding investor Kensington
Canopy Growth (NASDAQ: CGC - Get Free Report) and Clene (NASDAQ: CLNN - Get Free Report) are both sm
SALT LAKE CITY, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that ma
Clene NASDAQ: CLNN is preparing to submit a New Drug Application, or NDA, seeking accelerated approv
MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth. com a leading independent small cap media p
SALT LAKE CITY, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that man
Clene Inc. (CLNN) came out with a quarterly loss of $0.6 per share versus the Zacks Consensus Estima
Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pa
Clene NASDAQ: CLNN said it is preparing to submit a new drug application, or NDA, in early fourth qu
SALT LAKE CITY, July 29, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidia
Clene (CLNN) appears to have found support after losing some value lately, as indicated by the forma
Clene Inc. (CLNN) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estim
Clene (NASDAQ:CLNN) reported quarterly losses of $(0.69) per share which missed the analyst consensu
After successful completion of FDA Type C meeting, Clene expects to submit an NDA for CNM-Au8 ® unde
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiar
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiar
HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and ma
Clene Inc. (NASDAQ:CLNN) shares are up 6.68% on Monday as the company is filing for accelerated appr
FDA signals accelerated pathway for Clene's ALS drug CNM-Au8, with NDA filing planned and mixed
Mirum stock rises after Phase 2b VISTAS data for volixibat; AZURE-1 results and technical levels hig
Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidi
Clene (NASDAQ:CLNN) reported quarterly losses of $(0.88) per share which missed the analyst consensu
The FDA has granted an in-person Type C meeting during the first quarter of 2026 New independent ana
Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, "Clene" or the "Company") an
Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, "Clene" or the "Company") an
Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidi
Clene (NASDAQ:CLNN) reported quarterly losses of $(0.85) per share which missed the analyst consensu
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expe
During the session on Thursday, 461 stocks hit new 52-week lows.
Friday's session saw 169 companies set new 52-week lows.